Home - Telix Pharmaceuticals

Leading a new era in radiopharmaceuticals

Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic (‘theranostic’) products using targeted radiation.

Telix’s deep pipeline for prostate, kidney, brain (glioblastoma), and hematologic cancers, and rare diseases is underpinned by a reliable and secure global supply chain, manufacturing and distribution network.

Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent and has more than 20 clinical trials underway worldwide.

About Telix

One of the most expansive, late-stage research portfolios of diagnostic and therapeutic MTR candidates globally.

See Pipeline

Clinical Pipeline

One of the most expansive, late-stage research portfolios of diagnostic and therapeutic MTR candidates globally.

See Pipeline

Our lead imaging agent Illuccix®, approved by the FDA and TGA for use in the United States and Australia.

Illuccix®

Our lead imaging agent Illuccix®, approved by the FDA and TGA for use in the United States and Australia.

Illuccix®

Join our team driving innovation across cancer and rare diseases.

View opportunities

Careers at Telix

Join our team driving innovation across cancer and rare diseases.

View opportunities

FDA Approves Expanded Indication for Telix’s Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

Telix Pharmaceuticals today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) to enable its use for the selection of patients with metastatic prostate cancer, for whom 177Lu 177 PSMA-directed therapy is…

Changing the way we find and treat cancer and rare diseases

Leading a new era in radiopharmaceuticals

FDA Approves Expanded Indication for Telix’s Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

Telix’s ZIRCON Phase III Kidney Cancer Imaging Study Presented in “Game Changing” Session at EAU

Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU

Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive

Leading a new era in radiopharmaceuticals

FDA Approves Expanded Indication for Telix’s Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

Telix’s ZIRCON Phase III Kidney Cancer Imaging Study Presented in “Game Changing” Session at EAU

Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU

Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive

Subscribe